Casey Williams

2.5k total citations · 1 hit paper
57 papers, 1.6k citations indexed

About

Casey Williams is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Casey Williams has authored 57 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 23 papers in Cancer Research and 16 papers in Molecular Biology. Recurrent topics in Casey Williams's work include Cancer Genomics and Diagnostics (18 papers), Genetic factors in colorectal cancer (9 papers) and Advanced Breast Cancer Therapies (8 papers). Casey Williams is often cited by papers focused on Cancer Genomics and Diagnostics (18 papers), Genetic factors in colorectal cancer (9 papers) and Advanced Breast Cancer Therapies (8 papers). Casey Williams collaborates with scholars based in United States, United Kingdom and Germany. Casey Williams's co-authors include Brian Leyland‐Jones, Pradip De, Saleemul Huq, Debasis Bagchi, Manashi Bagchi, S.J. Stohs, J. Balmoori, Scott M. Lippman, Razelle Kurzrock and Shumei Kato and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Casey Williams

54 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study

2019 429 citations Jason K. Sicklick, Shumei Kato et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Casey Williams United States	18	527	460	414	266	196	57	1.6k
Scot Sedlacek United States	19	307 0.6×	909 2.0×	712 1.7×	208 0.8×	148 0.8×	41	1.8k
Elizabeth Anderson United Kingdom	16	676 1.3×	556 1.2×	625 1.5×	120 0.5×	149 0.8×	25	1.8k
Ikuo Kashiwakura Japan	23	659 1.3×	199 0.4×	217 0.5×	216 0.8×	65 0.3×	181	2.1k
Naoko Ishibe United States	18	516 1.0×	330 0.7×	387 0.9×	686 2.6×	297 1.5×	28	2.1k
Kimberly A. Lowe United States	25	276 0.5×	569 1.2×	290 0.7×	231 0.9×	294 1.5×	79	2.0k
Hung N. Luu United States	23	434 0.8×	370 0.8×	329 0.8×	224 0.8×	155 0.8×	102	1.7k
Ashraful Hoque United States	27	767 1.5×	556 1.2×	618 1.5×	558 2.1×	118 0.6×	64	2.2k
Rachel E. Ellsworth United States	25	1.1k 2.1×	720 1.6×	836 2.0×	191 0.7×	224 1.1×	91	2.2k
Beata Smolarz Poland	23	1.2k 2.2×	697 1.5×	728 1.8×	157 0.6×	258 1.3×	150	2.4k
Carolina Espina France	24	531 1.0×	698 1.5×	196 0.5×	134 0.5×	148 0.8×	73	1.9k

Countries citing papers authored by Casey Williams

Since Specialization

Citations

This map shows the geographic impact of Casey Williams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Casey Williams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Casey Williams more than expected).

Fields of papers citing papers by Casey Williams

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Casey Williams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Casey Williams. The network helps show where Casey Williams may publish in the future.

Co-authorship network of co-authors of Casey Williams

This figure shows the co-authorship network connecting the top 25 collaborators of Casey Williams. A scholar is included among the top collaborators of Casey Williams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Casey Williams. Casey Williams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Williams, Casey, et al.. (2025). CancerTrialMatch: a computational resource for the management of biomarker-based clinical trials at a community cancer center. Bioinformatics. 41(4).

Sun, Yuliang, et al.. (2024). Abstract 2554: Development/validation of a molecular and clinical evidence-based algorithm for selecting optimal precision therapeutic strategy for cancer patients - continuous study. Cancer Research. 84(6_Supplement). 2554–2554.

Starks, David, Luis Rojas‐Espaillat, Tobias Meißner, & Casey Williams. (2022). Phase I dose escalation study of dual PI3K/mTOR inhibition by Sapanisertib and Serabelisib in combination with paclitaxel in patients with advanced solid tumors. Gynecologic Oncology. 166(3). 403–409. 17 indexed citations

Xu, Bing, Christel M. Davis, Jason L. Petersen, et al.. (2020). Case report: 16-yr life history and genomic evolution of an ER⁺ HER2⁻ breast cancer. Molecular Case Studies. 6(6). a005629–a005629. 2 indexed citations

Sicklick, Jason K., Shumei Kato, Ryosuke Okamura, et al.. (2019). Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nature Medicine. 25(5). 744–750. 429 indexed citations breakdown →

De, Pradip, Jennifer Carlson, Brian Leyland‐Jones, Casey Williams, & Nandini Dey. (2018). Triple Fluorescence staining to Evaluate Mechanism-based Apoptosis following Chemotherapeutic and Targeted Anti-cancer Drugs in Live Tumor Cells. Scientific Reports. 8(1). 13192–13192. 10 indexed citations

Kato, Shumei, Nithya Krishnamurthy, Kimberly C. Banks, et al.. (2017). Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. Cancer Research. 77(16). 4238–4246. 90 indexed citations

Williams, Casey, et al.. (2017). Community-based adaptation (CBA): adding conceptual clarity to the approach, and establishing its principles and challenges. Climate and Development. 10(7). 577–589. 64 indexed citations

Bubalo, Joseph, Jon D. Herrington, Michael S. B. Edwards, et al.. (2017). Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer. Supportive Care in Cancer. 26(4). 1273–1279. 7 indexed citations

10.

Xu, Bing, et al.. (2017). Utilizing Tumor and Plasma Liquid Biopsy in Treatment Decision Making for an Estrogen Receptor-Positive Advanced Breast Cancer Patient. Cureus. 9(6). e1408–e1408. 14 indexed citations

11.

Dey, Nandini, Casey Williams, Brian Leyland‐Jones, & Pradip De. (2017). Mutation matters in precision medicine: A future to believe in. Cancer Treatment Reviews. 55. 136–149. 33 indexed citations

12.

Abramovitz, Mark, Casey Williams, Sibylle Loibl, & Brian Leyland‐Jones. (2016). Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer. Clinical Breast Cancer. 16(6). 444–455. 3 indexed citations

13.

McMahon, Caitlin, Casey Williams, Brian Leyland‐Jones, et al.. (2015). A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy. OncoTargets and Therapy. 8. 3561–3561. 7 indexed citations

14.

Willis, Scooter, Brandon Young, Casey Williams, & Brian Leyland‐Jones. (2014). Low Expression of FGD3, a Putative Guanine Nucleotide Exchange Factor for CDC42, is Prognostic of Poor Outcome in Breast Cancer. Annals of Oncology. 25. i18–i18. 1 indexed citations

15.

Gulbis, Alison, Kamakshi V. Rao, Joseph Bubalo, et al.. (2013). Utilization of Collaborative Practice Agreements between Physicians and Pharmacists as a Mechanism to Increase Capacity to Care for Hematopoietic Stem Cell Transplant Recipients. Biology of Blood and Marrow Transplantation. 19(4). 509–518. 31 indexed citations

16.

Grauer, Dennis, et al.. (2010). Effectiveness of Exogenous Albumin Administration for the Prevention of Ifosfamide‐Induced Encephalopathy. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 30(8). 812–817. 16 indexed citations

17.

Williams, Casey, Suzanne Day, Michael D. Reed, et al.. (2004). Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Biology of Blood and Marrow Transplantation. 10(9). 614–623. 26 indexed citations

18.

Bagchi, Debasis, et al.. (2002). Comparative effects of TCDD, endrin, naphthalene and chromium (VI) on oxidative stress and tissue damage in the liver and brain tissues of mice. Toxicology. 175(1-3). 73–82. 101 indexed citations

19.

Bagchi, Debasis, et al.. (2000). Role of p53 tumor suppressor gene in the toxicity of TCDD, endrin, naphthalene, and chromium (vi) in liver and brain tissues of mice. Free Radical Biology and Medicine. 28(6). 895–903. 24 indexed citations

20.

Kottaridis, PD, D W Milligan, Sakti Chakrabarti, et al.. (1999). A non myeloablative regimen for allografting high-risk patients: Low toxicity, stable engraftment without GVHD, disease control and potential for GVL with adoptive immunotherapy.. Blood. 94(10). 109039–109039. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact